Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Hyderabad: Granules India Limited has announced that the Company's Unit V facility located at Anakapally, Visakhapatnam, ...

The Board of Directors of Granules India Limited, at its meeting held today have approved the financial results of the ...

Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Quarterly Net Profit at Rs. 90.11 crore in December 2024 down 36.86% from Rs. 142.71 crore in December 2023. EBITDA stands at ...

Shares of Granules India Ltd. fell sharply on Friday after the pharmaceutical company reported a decline in its revenue and ...

Granules India’s net profit declined 6 per cent at ₹117 crore in the third quarter ended December 2024 compared to ₹125 crore ...

Motilal Oswal is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 665 in its ...